[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342257-105":59,"doc-detail-342257-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","research-advancements-in-nanoparticles-and-cell-based-drug-delivery-systems-for-the-targeted-killing-of-cancer-cells","Research advancements in nanoparticles and cell-based drug delivery systems for the targeted killing of cancer cells","","Nanotechnology in cancer therapy has significantly improved treatment precision, effectiveness, and safety, enabling more personalized patient care. Engineered smart nanoparticles and cell-based therapies aim to target tumor cells by sensing the tumor microenvironment (TME) while sparing healthy tissues. Nanoparticles can boost drug accumulation by enhancing solubilization and reducing degradation, and may address drug resistance by delivering multiple agents. However, patient-specific variability and regulatory approval remain key hurdles. The review summarizes nanoparticle and cell-based DDS types used in cancer research, including liposomes, micelles, protein and polymeric nanoparticles, and cell-based carriers such as macrophages, T-lymphocytes, dendritic cells, viruses, bacterial ghosts, minicells, SimCells, and outer membrane vesicles (OMVs), covering roles of TME in combination therapies from lab work to clinical use.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/research-advancements-in-nanoparticles-and-cell-based-drug-delivery-systems-for-the-targeted-killing-of-cancer-cells/342257/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/research-advancements-in-nanoparticles-and-cell-based-drug-delivery-systems-for-the-targeted-killing-of-cancer-cells/342257.png","ImageObject",300,407,{"name":92,"@type":93},"Theodora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",16,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How do engineered nanoparticles improve targeted cancer killing?","Question",{"text":113,"@type":114},"Engineered smart nanoparticles target tumor cells by sensing the tumor microenvironment (TME) and enhancing drug accumulation in tumors. They can solubilize insoluble compounds, prevent degradation, and deliver multiple drugs simultaneously.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What role does the tumor microenvironment (TME) play in drug delivery system design?",{"text":118,"@type":114},"The review highlights TME as a key determinant for developing smart drug delivery systems. TME conditions influence targeting, treatment effectiveness, and the development of combination therapies that integrate nanoparticles with cell-based approaches.",{"name":120,"@type":111,"acceptedAnswer":121},"What challenges remain for nanoparticle and cell-based therapies?",{"text":122,"@type":114},"Key challenges include patient-specific responses and regulatory approvals for cell-based or nanoparticle treatments. Additionally, complexities such as tumor heterogeneity, immune evasion, and drug resistance can limit consistent outcomes across patients.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},342257,1790097462,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","ONCOLOGY RESEARCH 2025 33(1): 27-44  \nREVIEW  \nResearch advancements in nanoparticles and cell-based drug delivery systems for the targeted killing of cancer cells  \nMERYEM A. ABDESSALEM; SIRIN A. ADHAM*  \nDepartment of Biology, College of Science, Sultan Qaboos University, Muscat, 123, Oman  \nKeywords: Drug delivery, Cancer, Nanoparticles, Liposomes, Micelles, Combination therapies, Targeted therapy, Precision medicine, Tumor microenvironment (TME)  \nAbstract: Nanotechnology in cancer therapy has signiﬁcantly advanced treatment precision, effectiveness, and safety, improving patient outcomes and personalized care. Engineered smart nanoparticles and cell-based therapies are designed to target tumor cells, precisely sensing the tumor microenvironment (TME) and sparing normal cells. These nanoparticles enhance drug accumulation in tumors by solubilizing insoluble compounds or preventing their degradation, and they can also overcome therapy resistance and deliver multiple drugs simultaneously. Despite these beneﬁts, challenges remain in patient-speciﬁc responses and regulatory approvals for cell-based or nanoparticle therapies. Cell-based drug delivery systems (DDSs) that primarily utilize the immune-recognition principle between ligands and receptors have shown promise in selectively targeting and destroying cancer cells. This review aims to provide a comprehensive overview of various nanoparticle and cell-based drug delivery system types used in cancer research. It covers approved and experimental nanoparticle therapies, including liposomes, micelles, protein-based and polymeric nanoparticles, as well as cell-based DDSs like macrophages, T-lymphocytes, dendritic cells, viruses, bacterial ghosts, minicells, SimCells, and outer membrane vesicles (OMVs) . The review also explains the role of TMEand its impact on developing smart DDSs in combination therapies and integrating nanoparticles with cell-based systems for targeting cancer cells. By detailing DDSs at different stages of development, from laboratory research to clinical trials and approved treatments, this review provides the latest insights and a collection of valuable citations of  \nthe innovative strategies that can be improved for the precise treatment of cancer.  \nAbbreviations ADXS11-001 AXAL  \nBGs  \nCAR-T  \nCe6  \nCEA  \ncRGD  \nDC  \nDDSs  \nDNA  \nEGFR  \nEPR  \nEVs  \nAxalimogene ﬁlolisbac  \nAxalimogene ﬁlolisbac Bacterial Ghosts  \nChimeric Antigen Receptor T-Cell Chlorin e6  \nCarcinoembryonic Antigen Cyclic arginine-glycine-aspartate Dendritic Cell  \nDrug Delivery Systems Deoxyribonucleic Acid Epidermal Growth Factor Receptor  \nEnhanced Permeability and Retention Extracellular Vesicles  \n*Address correspondence to: Sirin A. Adham, [sadham@squ.edu.om](sadham@squ.edu.om); [sirinadham@yahoo.com](sirinadham@yahoo.com)  \nReceived: 04 August 2024; Accepted: 07 November 2024;  \nPublished: 20 December 2024  \nFDA HER-2 HPV  \nHAS  \nIFN-γ LPS miRNA mRNA NDH-II NIR  \nNLRs  \nNSCLCOMVs PAMAMPD-1  \nPD-L1  \nPEG  \nPMMoV  \nrGO  \nFood and Drug Administration  \nHuman Epidermal Growth Factor Receptor 2 Human Papillomavirus  \nHuman Serum Albumin Interferon-γ Lipopolysaccharide Micro RNA  \nMessenger RNA  \nAlternative NADH Dehydrogenase Near Infrared Radiation  \nNOD-Like Receptors  \nNon-Small Cell Lung Carcinoma Outer Membrane Vesicles Polyamidoamine  \nProgrammed Death 1  \nProgrammed Death Ligand 1  \nPolyethylene Glycol Pepper Mild Mottle Virus Reduced Graphene Oxide  \nDoi: [10.32604/or.2024.056955 www.techscience.com/journal/or](10.32604/or.2024.056955 www.techscience.com/journal/or)  \nCopyright © 2025 The Authors. Published by Tech Science Press.  \nThis work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.  \n28 MERYEM A. ABDESSALEM et al.  \nRLRs RIG-I-Like Receptors  \nRNA Ribonucleic Acid  \nsiRNA Small Interfering RNA  \nTAMs Tumor-Associated Ma","cbCairfVY7srnlUL","https://ap.wps.com/l/cbCairfVY7srnlUL","pdf",9377107,18,"English","# Introduction\n## Challenges in cancer therapy and tumor heterogeneity\n## Tumor microenvironment (TME) and immune evasion\n## Drug resistance mechanisms and treatment variability\n# Review scope and system types\n## Smart nanoparticles and enhanced drug accumulation\n## Cell-based DDSs and immune-recognition targeting\n## Integration of TME-driven strategies and combination therapies","[{\"question\":\"How do engineered nanoparticles improve targeted cancer killing?\",\"answer\":\"Engineered smart nanoparticles target tumor cells by sensing the tumor microenvironment (TME) and enhancing drug accumulation in tumors. They can solubilize insoluble compounds, prevent degradation, and deliver multiple drugs simultaneously.\"},{\"question\":\"What role does the tumor microenvironment (TME) play in drug delivery system design?\",\"answer\":\"The review highlights TME as a key determinant for developing smart drug delivery systems. TME conditions influence targeting, treatment effectiveness, and the development of combination therapies that integrate nanoparticles with cell-based approaches.\"},{\"question\":\"What challenges remain for nanoparticle and cell-based therapies?\",\"answer\":\"Key challenges include patient-specific responses and regulatory approvals for cell-based or nanoparticle treatments. Additionally, complexities such as tumor heterogeneity, immune evasion, and drug resistance can limit consistent outcomes across patients.\"}]","Research advancements in nanoparticles and cell-based drug delivery systems for the targeted killing of cancer cells | PDF",1790045940,45,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a270a0db16f4a264bfb7180d98fe9997.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90206d3e68f8bdec287788fe4c295771.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b97642739f8e9fc484cc811502f5e21.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e33508dcbee12a368df30df733f4ee8.webp",980,1385]